Osteopontin: A biomarker to predict the outcome of inflammatory heart disease

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 2, 2010, Pages 195-202

  Klingel, Karin ^a   Kandolf, Reinhard ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cardiac remodeling; Fibrosis; Inflammation; Osteopontin; Virus myocarditis

Indexed keywords

COLLAGEN TYPE 1; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; MESSENGER RNA; OSTEOPONTIN; TRANSFORMING GROWTH FACTOR BETA;

ATHEROSCLEROSIS; CONGESTIVE CARDIOMYOPATHY; COXSACKIE VIRUS B; CYTOKINE PRODUCTION; CYTOLOGY; DISEASE COURSE; DISEASE MARKER; HEART DISEASE; HEART INJURY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; MYOCARDITIS; MYOFIBROBLAST; NONHUMAN; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE; VIRUS REPLICATION;

BIOLOGICAL MARKERS; HUMANS; IMMUNE SYSTEM PROCESSES; MYOCARDITIS; OSTEOPONTIN; PROGNOSIS;

EID: 77951611286     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1251504     Document Type: Review

References (46)

1. Martino T A., Liu P, Sole M J. Viral infection and the pathogenesis of dilated cardiomyopathy. Circ Res 1994 74 (2) 182-188 (Pubitemid 24029149)
2. Mason J W. Myocarditis and dilated cardiomyopathy: an inflammatory link. Cardiovasc Res 2003 60 (1) 5-10
3. Cocker M S., Abdel-Aty H, Strohm O, Friedrich M G. Age and gender effects on the extent of myocardial involvement in acute myocarditis: a cardiovascular magnetic resonance study. Heart 2009 95 (23) 1925-1930
4. Mahrholdt H, Wagner A, Deluigi C C. et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006 114 (15) 1581-1590 (Pubitemid 44547428)
5. Knipe D M., Howley P M. Fields Virology. 4th ed. Philadelphia, PA Lippincott-Raven 2001
6. Klingel K, Sauter M, Bock C T., Szalay G, Schnorr J J., Kandolf R. Molecular pathology of inflammatory cardiomyopathy. Med Microbiol Immunol (Berl) 2004 193 (2-3) 101-107 (Pubitemid 38703777)
7. Grist N R., Bell E J., Assaad F. Enteroviruses in human disease. Prog Med Virol 1978 24 114-157
8. Kindermann I, Kindermann M, Kandolf R et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008 118 (6) 639-648
9. Klingel K, Hohenadl C, Canu A et al. Ongoing enterovirus-induced myocarditis is associated with persistent heart muscle infection: quantitative analysis of virus replication, tissue damage, and inflammation. Proc Natl Acad Sci U S A 1992 89 (1) 314-318
10. Fairweather D, Frisancho-Kiss S, Yusung S A. et al. Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart. Am J Pathol 2004 165 (6) 1883-1894 (Pubitemid 39578368)
11. Szalay G, Sauter M, Hald J, Weinzierl A, Kandolf R, Klingel K. Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin-10 disorders. Am J Pathol 2006 169 (6) 2085-2093 (Pubitemid 351181968)
12. Li J, Schwimmbeck P L., Tschope C et al. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res 2002 56 (2) 235-247 (Pubitemid 35223494)
13. Heymans S, Pauschinger M, De Palma A et al. Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 2006 114 (6) 565-573 (Pubitemid 44199646)
14. Lang C, Sauter M, Szalay G et al. Connective tissue growth factor: a crucial cytokine-mediating cardiac fibrosis in ongoing enterovirus myocarditis. J Mol Med 2008 86 (1) 49-60
15. Mazzali M, Kipari T, Ophascharoensuk V et al. Osteopontina molecule for all seasons. QMJ 2002 95 3-13
16. O'Regan A W., Chupp G L., Lowry J A., Goetschkes M, Mulligan N, Berman J S. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J Immunol 1999 162 (2) 1024-1031 (Pubitemid 29035430)
17. Graf K, Stawowy P. Osteopontin: a protective mediator of cardiac fibrosis? Hypertension 2004 44 (6) 809-810 (Pubitemid 39577403)
18. Wang K X., Denhardt D T. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008 19 (5-6) 333-345
19. Okamoto H. Osteopontin and cardiovascular system. Mol Cell Biochem 2007 300 (12) 1-7 (Pubitemid 46881810)
20. Giachelli C M., Liaw L, Murry C E., Schwartz S M., Almeida M. Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci 1995 760 109-126
21. Singh K, Sirokman G, Communal C et al. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension 1999 33 (2) 663-670 (Pubitemid 29091644)
22. Trueblood N A., Xie Z, Communal C et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res 2001 88 (10) 1080-1087 (Pubitemid 34137122)
23. Murry C E., Giachelli C M., Schwartz S M., Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 1994 145 (6) 1450-1462 (Pubitemid 24378499)
24. Williams E B., Halpert I, Wickline S, Davison G, Parks W C., Rottman J N. Osteopontin expression is increased in the heritable cardiomyopathy of Syrian hamsters. Circulation 1995 92 (4) 705-709
25. Shin T, Ahn M, Kim H, Kim H M., Matsumoto Y. Increased expression of osteopontin in the heart tissue of Lewis rats with experimental autoimmune myocarditis. J Vet Med Sci 2006 68 (4) 379-382
26. Szalay G, Sauter M, Haberland M et al. Osteopontin: a fibrosis-related marker molecule in cardiac remodeling of enterovirus myocarditis in the susceptible host. Circ Res 2009 104 (7) 851-859
27. Mukherjee B B., Nemir M, Beninati S et al. Interaction of osteopontin with fibronectin and other extracellular matrix molecules. Ann N Y Acad Sci 1995 760 201-212
28. Kaartinen M T., Pirhonen A, Linnala-Kankkunen A, Menp P H. Cross-linking of osteopontin by tissue transglutaminase increases its collagen binding properties. J Biol Chem 1999 274 (3) 1729-1735 (Pubitemid 129507768)
29. Lenga Y, Koh A, Perera A S., McCulloch C A., Sodek J, Zohar R. Osteopontin expression is required for myofibroblast differentiation. Circ Res 2008 102 (3) 319-327 (Pubitemid 351271652)
30. O'Regan A, Berman J S. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 2000 81 (6) 373-390 (Pubitemid 32291179)
31. Scatena M, Liaw L, Giachelli C M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007 27 (11) 2302-2309 (Pubitemid 350203943)
32. Ashkar S, Weber G F., Panoutsakopoulou V et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000 287 (5454) 860-864 (Pubitemid 30084330)
33. Yu Q, Vazquez R, Khojeini E V., Patel C, Venkataramani R, Larson D F. IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am J Physiol Heart Circ Physiol 2009 297 (1) H76-H85
34. Abel B, Freigang S, Bachmann M F., Boschert U, Kopf M. Osteopontin is not required for the development of Th1 responses and viral immunity. J Immunol 2005 175 (9) 6006-6013 (Pubitemid 41508086)
35. Abel B, Kurrer M, Shamshiev A et al. The osteopontin-CD44 pathway is superfluous for the development of autoimmune myocarditis. Eur J Immunol 2006 36 494-499 (Pubitemid 43257472)
36. Shinohara M L., Lu L, Bu J et al. Osteopontin expression is essential for interferon- production by plasmacytoid dendritic cells. Nat Immunol 2006 7 (5) 498-506
37. Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, Hiramori K. Myocardial osteopontin expression is associated with collagen fibrillogenesis in human dilated cardiomyopathy. Eur J Heart Fail 2005 7 (5) 755-762 (Pubitemid 41125889)
38. Stawowy P, Blaschke F, Pfautsch P et al. Increased myocardial expression of osteopontin in patients with advanced heart failure. Eur J Heart Fail 2002 4 (2) 139-146 (Pubitemid 34233499)
39. Atalar E, Ozturk E, Ozer N et al. Plasma soluble osteopontin concentrations are increased in patients with rheumatic mitral stenosis and associated with the severity of mitral valve calcium. Am J Cardiol 2006 98 (6) 817-820 (Pubitemid 44301020)
40. Canver C C., Gregory R D., Cooler S D., Voytovich M C. Association of osteopontin with calcification in human mitral valves. J Cardiovasc Surg (Torino) 2000 41 (2) 171-174 (Pubitemid 30386514)
41. Georgiadou P, Iliodromitis E K., Varounis C et al. Relationship between plasma osteopontin and oxidative stress in patients with coronary artery disease. Expert Opin Ther Targets 2008 12 (8) 917-920
42. Suezawa C, Kusachi S, Murakami T et al. Time-dependent changes in plasma osteopontin levels in patients with anterior-wall acute myocardial infarction after successful reperfusion: correlation with left-ventricular volume and function. J Lab Clin Med 2005 145 (1) 33-40 (Pubitemid 40139075)
43. Arnlv J, Evans J C., Benjamin E J. et al. Clinical and echocardiographic correlates of plasma osteopontin in the community: the Framingham Heart Study. Heart 2006 92 (10) 1514-1515
44. Bazzichi L, Ghiadoni L, Rossi A et al. Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis. Mol Med 2009 15 (1112) 402-406
45. Chen Y J., Shen J L., Wu C Y., Chang Y T., Chen C M., Lee F Y. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol 2009 60 (2) 225-230
46. Schoensiegel F, Bekeredjian R, Schrewe A et al. Atrial natriuretic peptide and osteopontin are useful markers of cardiac disorders in mice. Comp Med 2007 57 (6) 546-553